Nastaran Zahir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nastaran Zahir has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Corinne Boulanger-Espeut
National Cancer Institute , National Institutes of Health, Rockville, MD, 20850, USA
3 shared publicationsMichael Schmidt
National Cancer Institute , National Institutes of Health, Rockville, MD, 20850, USA
3 shared publicationsOliver Bogler
National Cancer Institute , National Institutes of Health, Rockville, MD, 20850, USA
3 shared publicationsSasha Torres
National Cancer Institute , National Institutes of Health, Rockville, MD, 20850, USA
3 shared publicationsGrace Liou
National Cancer Institute, National Institutes of Health, Rockville, USA
2 shared publicationsNan Ma
Digital Science, Inc, Cambridge, USA
2 shared publications
Latest Publications
- Open Access
- 22 May 2026
- Published by Springer Nature in Journal of Cancer Education
Outcome Evaluation of NCI Clinical Scientist Research Career Development Award (K08) Program
Clinical Scientists are an integral part of advancements in biomedicine as they leverage their expertise in the clinical aspects of disease when conducting scientific research. These investigators face several factors that can impact their advancement to independent research careers such as having sufficient protected time to devote to academic work outside of clinical duties and the funds to support their research efforts. The National Cancer Institute (NCI) Clinical Scientist Research Career Development Award (K08) is designed for this career path, and provides the necessary protected time for an intensive, supervised research career development experience, salary, as well as mentored guidance to help clinical scientists advance to independence. We analyzed former K08 awardees, as well as unfunded applicants to determine how receiving an NCI K08 award impacted research careers in terms of attaining substantive R01 or R01-equivalent (R01eq) awards, timing of R01eq awards, and institutional support. This information was additionally supported by surveys and interviews with K08 awardees with one or more R01eq awards, K08 awardees with no subsequent R01eq awards, and early-stage investigators that did not apply for the NCI K08 award. Results show that programmatic changes in Fiscal Year (FY) 2018 allowing for increased salary and research development support resulted in a more than threefold increase of K08 applications by FY 2024. This corresponds with an increase in NCI investment in the K08 program that exceeded $50 million in FY 2024. Awardees also hold more active grants from the National Institutes of Health (NIH) and are located at more resource-rich institutions than those without an NCI K08 award. These results also show a slight delay in transition to independence as measured by time to first R01 award by K08 awardees. Survey respondents highlighted protected time as one of the most impactful factors towards establishing research independence while noting low salaries and insufficient research budgets remain as barriers. The NCI K08 program is important in the development and retention of clinical scientists and aiding them in achieving research independence. Potential program changes such as increased resource funds, decreased time of award duration, and post-award career development support for transition to independence may further improve K08 outcomes.
- 22 May 2026
- Published by Springer Nature in Journal of Cancer Education
Open AccessOutcome Evaluation of NCI Clinical Scientist Research Career Development Award (K08) Program
Clinical Scientists are an integral part of advancements in biomedicine as they leverage their expertise in the clinical aspects of disease when conducting scientific research. These investigators face several factors that can impact their advancement to independent research careers such as having sufficient protected time to devote to academic work outside of clinical duties and the funds to support their research efforts. The National Cancer Institute (NCI) Clinical Scientist Research Career Development Award (K08) is designed for this career path, and provides the necessary protected time for an intensive, supervised research career development experience, salary, as well as mentored guidance to help clinical scientists advance to independence. We analyzed former K08 awardees, as well as unfunded applicants to determine how receiving an NCI K08 award impacted research careers in terms of attaining substantive R01 or R01-equivalent (R01eq) awards, timing of R01eq awards, and institutional support. This information was additionally supported by surveys and interviews with K08 awardees with one or more R01eq awards, K08 awardees with no subsequent R01eq awards, and early-stage investigators that did not apply for the NCI K08 award. Results show that programmatic changes in Fiscal Year (FY) 2018 allowing for increased salary and research development support resulted in a more than threefold increase of K08 applications by FY 2024. This corresponds with an increase in NCI investment in the K08 program that exceeded $50 million in FY 2024. Awardees also hold more active grants from the National Institutes of Health (NIH) and are located at more resource-rich institutions than those without an NCI K08 award. These results also show a slight delay in transition to independence as measured by time to first R01 award by K08 awardees. Survey respondents highlighted protected time as one of the most impactful factors towards establishing research independence while noting low salaries and insufficient research budgets remain as barriers. The NCI K08 program is important in the development and retention of clinical scientists and aiding them in achieving research independence. Potential program changes such as increased resource funds, decreased time of award duration, and post-award career development support for transition to independence may further improve K08 outcomes.
- Open Access
- 16 May 2024
- Published by Springer Nature in Journal of Cancer Education
- Vol. 39 (5) , 504-506
Correction: Evaluation of the National Cancer Institute (NCI) Pathway to Independence Award (K99/R00) Program
- 16 May 2024
- Published by Springer Nature in Journal of Cancer Education
- Vol. 39 (5) , 504-506
Open AccessCorrection: Evaluation of the National Cancer Institute (NCI) Pathway to Independence Award (K99/R00) Program
- Open Access
- 18 March 2024
- Published by Springer Nature in Journal of Cancer Education
- Vol. 39 (5) , 490-503
Evaluation of the National Cancer Institute (NCI) Pathway to Independence Award (K99/R00) Program
The National Cancer Institute (NCI) K99/R00 award is intended to help postdoctoral scholars transition in a timely manner to research independence and to foster their development of an impactful cancer research program that is competitive for subsequent independent funding. Here we analyzed factors that impact peer review outcomes and evaluated whether NCI K99/R00 awardees have achieved the goals of the K99/R00 funding mechanism. Our analysis of the K99/R00 review criterion scores demonstrates that while all review criterion scores are positively correlated with the overall impact score, the Research Plan criterion is the strongest predictor of the overall impact score and funding outcomes. In addition, our analysis shows the NCI K99/R00 award facilitated the successful transition of postdoctoral scholars to research independence and enhanced the likelihood of K99/R00 awardees to secure subsequent R01-equivalent NIH grant support although not in an accelerated fashion as originally intended. An NCI K99/R00 award was not determined to be a prerequisite to obtain a faculty position, but for some awardees, it was an asset in that transition. Our results suggest that the NCI K99/R00 award is an important component for training and retention of the next generation of independent cancer researchers and to increasing the percentage of women and promoting the diversity of the cancer research workforce.
- 18 March 2024
- Published by Springer Nature in Journal of Cancer Education
- Vol. 39 (5) , 490-503
Open AccessEvaluation of the National Cancer Institute (NCI) Pathway to Independence Award (K99/R00) Program
The National Cancer Institute (NCI) K99/R00 award is intended to help postdoctoral scholars transition in a timely manner to research independence and to foster their development of an impactful cancer research program that is competitive for subsequent independent funding. Here we analyzed factors that impact peer review outcomes and evaluated whether NCI K99/R00 awardees have achieved the goals of the K99/R00 funding mechanism. Our analysis of the K99/R00 review criterion scores demonstrates that while all review criterion scores are positively correlated with the overall impact score, the Research Plan criterion is the strongest predictor of the overall impact score and funding outcomes. In addition, our analysis shows the NCI K99/R00 award facilitated the successful transition of postdoctoral scholars to research independence and enhanced the likelihood of K99/R00 awardees to secure subsequent R01-equivalent NIH grant support although not in an accelerated fashion as originally intended. An NCI K99/R00 award was not determined to be a prerequisite to obtain a faculty position, but for some awardees, it was an asset in that transition. Our results suggest that the NCI K99/R00 award is an important component for training and retention of the next generation of independent cancer researchers and to increasing the percentage of women and promoting the diversity of the cancer research workforce.
- Open Access
- 2 April 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (5)
Matrix compliance permits NF-κB activation to drive therapy resistance in breast cancer
Triple-negative breast cancers (TNBCs) are associated with poor survival mediated by treatment resistance. TNBCs are fibrotic, yet little is known regarding how the extracellular matrix (ECM) evolves following therapy and whether it impacts treatment response. Analysis revealed that while primary untreated TNBCs are surrounded by a rigid stromal microenvironment, chemotherapy-resistant residual tumors inhabit a softer niche. TNBC organoid cultures and xenograft studies showed that organoids interacting with soft ECM exhibit striking resistance to chemotherapy, ionizing radiation, and death receptor ligand TRAIL. A stiff ECM enhanced proapoptotic JNK activity to sensitize cells to treatment, whereas a soft ECM promoted treatment resistance by elevating NF-κB activity and compromising JNK activity. Treatment-resistant residual TNBCs residing within soft stroma had elevated activated NF-κB levels, and disengaging NF-κB activity sensitized tumors in a soft matrix to therapy. Thus, the biophysical properties of the ECM modify treatment response, and agents that modulate stiffness-dependent NF-κB or JNK activity could enhance therapeutic efficacy in patients with TNBC.
- 2 April 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (5)
Open AccessMatrix compliance permits NF-κB activation to drive therapy resistance in breast cancer
Triple-negative breast cancers (TNBCs) are associated with poor survival mediated by treatment resistance. TNBCs are fibrotic, yet little is known regarding how the extracellular matrix (ECM) evolves following therapy and whether it impacts treatment response. Analysis revealed that while primary untreated TNBCs are surrounded by a rigid stromal microenvironment, chemotherapy-resistant residual tumors inhabit a softer niche. TNBC organoid cultures and xenograft studies showed that organoids interacting with soft ECM exhibit striking resistance to chemotherapy, ionizing radiation, and death receptor ligand TRAIL. A stiff ECM enhanced proapoptotic JNK activity to sensitize cells to treatment, whereas a soft ECM promoted treatment resistance by elevating NF-κB activity and compromising JNK activity. Treatment-resistant residual TNBCs residing within soft stroma had elevated activated NF-κB levels, and disengaging NF-κB activity sensitized tumors in a soft matrix to therapy. Thus, the biophysical properties of the ECM modify treatment response, and agents that modulate stiffness-dependent NF-κB or JNK activity could enhance therapeutic efficacy in patients with TNBC.
- 7 November 2020
- Published by Elsevier in Trends in Cancer
- Vol. 7 (1) , 3-9
Education and Outreach in Physical Sciences in Oncology
- 7 November 2020
- Published by Elsevier in Trends in Cancer
- Vol. 7 (1) , 3-9
Education and Outreach in Physical Sciences in Oncology
- Open Access
- 1 January 2018
- Published by Springer Nature
- Vol. 1092, 1-10
The National Cancer Institute Investment in Biomechanics in Oncology Research
The qualitative description of tumors feeling stiffer than surrounding normal tissue has been long appreciated in the clinical setting. These empirical observations have been corroborated by the precise measurement and characterization of mechanical properties of cancerous tissues. Much of the advancement in our understanding of mechanics in oncology has been enabled by the development of innovative technologies designed to probe cells and tissues as well as integrative software analysis tools that facilitate biological interpretation and generation of testable hypotheses. While some mechanics in oncology research has been investigatorinitiated and supported by the National Cancer Institute (NCI), several NCI programs described herein have helped to foster the growth of the burgeoning field. Programs highlighted in this chapter include Innovative Molecular Analysis Technologies (IMAT), Physical Sciences-Oncology Network (PSON), Tumor Microenvironment Network (TMEN), Integrative Cancer Biology Program (ICBP), and the Cancer Systems Biology Consortium (CSBC). This chapter showcases the scientific contributions of these programs to the field of biomechanics in oncology.
- 1 January 2018
- Published by Springer Nature
- Vol. 1092, 1-10
Open AccessThe National Cancer Institute Investment in Biomechanics in Oncology Research
The qualitative description of tumors feeling stiffer than surrounding normal tissue has been long appreciated in the clinical setting. These empirical observations have been corroborated by the precise measurement and characterization of mechanical properties of cancerous tissues. Much of the advancement in our understanding of mechanics in oncology has been enabled by the development of innovative technologies designed to probe cells and tissues as well as integrative software analysis tools that facilitate biological interpretation and generation of testable hypotheses. While some mechanics in oncology research has been investigatorinitiated and supported by the National Cancer Institute (NCI), several NCI programs described herein have helped to foster the growth of the burgeoning field. Programs highlighted in this chapter include Innovative Molecular Analysis Technologies (IMAT), Physical Sciences-Oncology Network (PSON), Tumor Microenvironment Network (TMEN), Integrative Cancer Biology Program (ICBP), and the Cancer Systems Biology Consortium (CSBC). This chapter showcases the scientific contributions of these programs to the field of biomechanics in oncology.